|Slideshows|February 2, 2017

Antipsychotic Augmentation vs Monotherapy in Schizophrenia

To augment or not to augment? That is the question.

View the slides in PDF format. Also see: Antipsychotics and Breast Cancer Risk.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Latest CME

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?
Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

View more
Optimizing Care for Patients With Tardive Dyskinesia
Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

View more
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

View more